TABLE 2

Examples of clinical studies that have tested JAKi and HDACi for cancer therapy

DrugsPhaseChemotypesCondition or DiseaseClinical Trial IdentifierStatus
Panobinostat (pan-HDACi) +ruxolitinib
(JAK1/JAK2 inhibitor)		IbHydroxamic acid+
pyrazole		(N = 61); PMF,
post-PV MF, post-
ET MF		#NCT01433445Completed
Panobinostat (pan-HDACi) + ruxolitinib
(JAK1/JAK2 inhibitor)		I/IIHydroxamic acid+
pyrazole		(N = 20); PMF,
post-PV MF, post-
ET MF		#NCT01693601Completed
Panobinostat(pan-HDACi) + ruxolitinib
(JAK1/JAK2 inhibitor)		IVHydroxamic acid+
pyrazole		(N = 410); PMF,
post-PV MF, post-
ET MF and CIMF		#NCT02386800Recruiting
Pracinostat (pan-HDACi) + ruxolitinib
(JAK1/JAK2 inhibitor)		I/IIHydroxamic acid+
pyrazole		(N = 25); PMF,
post-PV MF, post-
ET MF		#NCT02267278Completed
Chidamide (inhibits HDAC1,2,3,10) + tofacitinib
(JAK3 inhibitor)		I/IIBenzamide+
pyrazole		(N = 20); extranodal
NK/T-cell lymphoma		#NCT03598959Not yet recruiting

  • CIMF, chronic idiopathic myelofibrosis; PMF, primary myelofibrosis.